Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 2/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154705 | 0.78 | MAOA (0.39) | MAOAMAOBOXTRACHELMNA | |
| SCHEMBL9116482 | 0.71 | MAOA (0.37) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL29434883 | 0.67 | MAOA (0.41) | MAOAMAOBOXTRLMNACRHBP | |
| SCHEMBL9209 | 0.67 | MAOA (0.41) | MAOAMAOBOXTRLMNACRHBP | |
| SCHEMBL1420110 | 0.67 | MAOA (0.41) | MAOAMAOBOXTRLMNACRHBP | |
| SCHEMBL7197365 | 0.67 | MAOA (0.41) | MAOAMAOBOXTRLMNACRHBP | |
| SCHEMBL2143603 | 0.65 | MAOA (0.39) | MAOAMAOBOXTRLMNACRHBP | |
| SCHEMBL151338 | 0.65 | MAOA (0.39) | MAOAMAOBOXTRLMNACRHBP | |
| SCHEMBL39996 | 0.65 | MAOA (0.39) | MAOAMAOBOXTRLMNACRHBP | |
| SCHEMBL4860431 | 0.65 | MAOA (0.39) | MAOAMAOBOXTRLMNACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902381-B2 | Synthesising method and benzoxathiepine intermediates | PIERRE FABRE MEDICAMENT (FR) | 2011-03-08 | — | — | US | claimed |
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | PIERRE FABRE MEDICAMENT (FR) | 2008-09-25 | — | — | US | claimed |
| EP-1735297-B1 | SYNTHESISING METHOD AND BENZOXATHIEPINE INTERMEDIATES | PF MEDICAMENT (FR) | 2007-10-03 | — | — | EP | claimed |
| EP-1735297-A1 | SYNTHESISING METHOD AND BENZOXATHIEPINE INTERMEDIATES | PIERRE FABRE MEDICAMENT (FR) | 2006-12-27 | — | — | EP | claimed |
| WO-2005103027-A1 | SYNTHESISING METHOD AND BENZOXATHIEPINE INTERMEDIATES | PIERRE FABRE MEDICAMENT (FR) | 2005-11-03 | — | — | WO | claimed |
| EP-0145494-B1 | 1,5-BENZOXATHIEPIN DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-11-08 | — | — | EP | claimed |
| EP-0300088-A2 | 1,5-Benzoxathiepin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-01-25 | — | — | EP | claimed |
| US-4751316-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-14 | — | — | US | claimed |
| US-4672064-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-09 | — | — | US | claimed |
| EP-0145494-A2 | 1,5-Benzoxathiepin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | claimed |
| CN-120136870-A | GLP-1 receptor targeting compounds and uses thereof | 信达生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119677738-A | Compounds and uses thereof | 福宏治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-118871614-A | Method of selective deposition and chemical delivery system | 朗姆研究公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114805286-A | Preparation method of naphtho-oxo-thiazepine derivative | 深圳职业技术学院 | 2022-07-29 | — | — | CN | disclosed |
| CN-112654627-A | Heterocyclic compounds | 大塚制药株式会社 | 2021-04-13 | — | — | CN | disclosed |
| EP-0300088-A2 | 1,5-Benzoxathiepin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-01-25 | — | — | EP | disclosed |
| US-4751316-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| US-4672064-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-09 | — | — | US | disclosed |
| WO-1985004658-A1 | 1,5-BENZOXATHIEPINE DERIVATIVES AND THEIR PREPARATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-24 | — | — | WO | disclosed |
| EP-0145494-A2 | 1,5-Benzoxathiepin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | CYP2F1, CYP2E1, CBR1 | MAOA 120/4885MAOB 83/4885OXTR 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.